BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Cancer Chengdu Chipscreen Pharmaceutical describes new WRN inhibitors Dec. 2, 2025 Chengdu Chipscreen Pharmaceutical Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. BioWorld ScienceCancerPatents